Daily Analysis on

AUROPHARMA

Technical View As seen in the daily

chart, the stock showed high volatility today. Opened at ₹1070, made a high of ₹1071, low of ₹1040.20, and closed at ₹1046.40. The stock is facing resistance near the 14-day EMA and failed to close above ₹1080, indicating no short-term buy signal yet. On the weekly chart, the stock is holding support near the 200-day EMA and the crucial ₹995 zone. In the long term, any dip towards the ₹1000–1020 zone could provide a buy-on-dips opportunity. Upside potential: Over the next 6–8 months, the stock may retest the ₹1250–1300 levels if support sustains. Upcoming Events & Impact Q2 FY26 Results (November 2025) → Expected to reflect better US business traction. Positive results could trigger momentum. Product Launches in US/Europe → Likely to enhance revenue visibility. USFDA Inspection Outcomes → Any adverse report may negatively impact the stock in short term. Global Drug Pricing Trends → A major determinant of profitability.